> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Industry MIDD Paired Meeting Program Benefits Cited
- URL: https://www.fdaweb.com/industry-midd-paired-meeting-program-benefits-cited/
- Published: 2021-06-16T12:00:00.000Z
- Updated: 2026-09-14T17:03:41.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5149550

Drug company representatives say their experience with the FDA MIDD (Model-Informed Drug Development) paired meeting program has been strongly favorable. “The companies have recognized savings in resources, achieved alignment with FDA on developmental strategies, and gained clarity on important aspects of programs and product characteristics,” an open-source [report](https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.2265?ref=fdaweb.com) in *Clinical Pharmacology and Therapeutics* says.

The report is based on a survey of participating companies conducted by the International Consortium for Innovation and Quality in Pharmaceutical Development.

“The totality of evidence on the value of this program demonstrates a definite benefit to patients, the medical community, and pharmaceutical companies,” the report says. “Hence, the permanent adoption and expansion of these meetings and their principles is strongly encouraged.”

The main goals of the program are cited as **(1)** providing an opportunity for drug developers and FDA to discuss the application of MIDD approaches to the development and regulatory evaluation of medical products, and **(2)** providing advice about how particular MIDD approaches can be used in a specific drug development program.

Since the program’s inception in 2018 through the first quarter of 2021, the report says, FDA has received 34 meeting requests and granted 30 of them. There have been projects at every stage of development and spanning a large number of therapeutic areas.